Skip to main content
OpenTrials
Completed

NCT Number: NCT04456829

Investigation of the Efficacies of a Resveratrol Formula on Improvement of Skin Conditions and Inflammatory Related Factors

To assess a resveratrol formula on improvement of skin conditions and inflammatory cytokines in blood

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Conditions Proinflammatory Cytokines Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chia Nan University of Pharmacy & Science

Tainan, 71710, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers aged above 20 years old

Exclusion criteria

  • Subject who is not willing to participate in this study.
  • Patients with diseases of the skin, heart, liver, kidney, endocrine and other organs and patients with mental illness (according to medical history).
  • Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks.
  • Subjects who have large spots (area >3 square centimeter) or abnormal acne.

Treatment and study plan

Resveratrol drink

Dietary Supplement

Subjects will consume a bottle of resveratrol drink for two months.

Other names: Grape Yeast Compound Fruit Vegetable Beverage

Placebo drink

Dietary Supplement

Subjects will consume a bottle of placebo drink for two months.

Primary outcomes

  1. The change of skin moisture

    Time frame: 0, 4, and 8 weeks

    Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

  2. The change of skin elasticity

    Time frame: 0, 4, and 8 weeks

    Cutometer® dual MPA 580 was utilized to measure skin elasticity (parameter R2). Units: μm penetration depth into the probe opening, expressed as curves

  3. The change of skin wrinkles

    Time frame: 0, 4, and 8 weeks

    VISIA Complexion Analysis System was utilized to measure wrinkles. Units: arbitrary units

  4. The change of skin collagen density

    Time frame: 0, 4, and 8 weeks

    DermaLab® USB - 20 MHz High Freq. Ultrasound probe was utilized to scan and analyze skin collagen density. Units:

    Intensity score

  5. The change of skin texture

    Time frame: 0, 4, and 8 weeks

    VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

  6. The change of skin pores

    Time frame: 0, 4, and 8 weeks

    VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units

  7. The change of total antioxidant capacity of blood

    Time frame: 0 and 8 weeks

    Total Antioxidant Capacity Assay Kit

  8. The change of TNF-alpha of blood

    Time frame: 0 and 8 weeks

    ELISA Kit

  9. The change of IL-6 of blood

    Time frame: 0 and 8 weeks

    ELISA Kit

  10. The change of IL-17 of blood

    Time frame: 0 and 8 weeks

    ELISA Kit

  11. The change of IL-1β of blood

    Time frame: 0 and 8 weeks

    ELISA Kit

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Official study title

Investigation of the Efficacies of a Resveratrol Formula on Improvement of Skin

Acronym: Resveratrol

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 7, 2020
Registry last updated
Jan 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.